Hydrodynamics of the Certas™ programmable valve for the treatment of hydrocephalus
© Eklund et al.; licensee BioMed Central Ltd. 2012
Received: 23 March 2012
Accepted: 29 May 2012
Published: 29 June 2012
The new Certas™ shunt for the treatment of hydrocephalus has seven standard pressure settings that according to the manufacturer range from 36 to 238 mmH2O, and an additional “Virtual Off” setting with an opening pressure >400 mmH2O. Information on actual pressure response and reliability of shunt performance is important in clinical application, especially the “Virtual Off” setting as a non-surgical replacement for shunt ligation. The objective of this study was to evaluate the in-vitro hydrodynamic performance of the Certas™ shunt.
Six new Certas™ shunts with proximal and distal catheters were tested with an automated, computerized test system that raised the pressure from zero to a maximum pressure and back to zero at each valve setting. Opening pressure and flow resistance were determined.
For settings 1–7 the measured opening pressure range was 26 to 247 mmH2O, and the mean change in opening pressure for a one-step adjustment was between 33 and 38 mmH2O. For setting 8 (“Virtual Off”) the measured mean opening pressure was 494 ± 34 mmH2O (range 451 to 556 mmH2O). The mean outflow resistance was 7.0 mmHg/ml/min (outflow conductance 17.9 μl/s/kPa).
The six shunts had similar characteristics and closely matched the manufacturer’s specifications for opening pressure at settings 1–7. The opening pressure for the “Virtual Off” setting was nearly 500 mmH2O, which is 100 mmH2O higher than the manufacturer’s specification of “>400” and should be functionally off for most patients with communicating hydrocephalus. Clinical studies are needed to evaluate if the CSF dynamic profile persists after implantation in patients.
Improvements in the modern shunt for drainage of cerebrospinal fluid (CSF) in the surgical treatment of hydrocephalus have aimed to include features in shunt design that reduce complications and improve clinical outcome. One goal has been to increase control over the amount of CSF drainage, such as adjustable shunt valves that permit postoperative adjustment of the shunt valve opening pressure. Several different brands of adjustable CSF shunts are available, characterized by opening pressures ranging from approximately 0 to 200 mm H2O, depending on the brand and the model. If a patient’s clinical response after shunt surgery is inadequate, lowering the shunt valve opening pressure may improve outcome while avoiding surgery to remove and replace the shunt valve. Alternately, in patients with over-drainage symptoms of headache or hearing change, or signs such as subacute or chronic subdural effusion or hemorrhage, treatment can be initiated by increasing the shunt valve opening pressure, thus avoiding surgery . In several clinical settings, such as subacute or chronic subdural fluid collections, or efforts to achieve shunt independence, the clinician may prefer to stop CSF drainage. There is currently no valve system that provides this option, and even adjustable valves must be disabled by surgical ligation of the system because flow through the shunt is still possible at a valve opening pressure of 200 mmH2O.
The Codman Certas™ programmable valve was approved for clinical use in both Europe and the US in 2011. The Certas™ is an adjustable shunt with 7 pressure settings that range, according to the manufacturer, from 36 to 238 mm H2O. An interesting feature of the shunt is an eighth setting with a very high opening pressure (>400 mm H2O), that is described as “Virtual Off”. The aim of our study was to evaluate the hydrodynamic characteristics of the Certas™ programmable valve with an in-vitro bench test system.
The CSF shunts
Six new Certas™ shunts without a SiphonGuard™ were purchased from Codman (Wokingham, UK). The shunts were tested with the original 14 cm proximal and 120 cm distal catheters. The proximal (ventricular) catheter was shortened approximately two centimeter in order to remove the perforated part so that it could be attached to the test rig for perfusion.
The test system
To simulate the effect of subcutaneous tissue pressure on the valve mechanism , the shunt was submerged in water at a depth of 100 mm. The distal catheter was led to an overflow container with a water level held constant at the zero pressure level to ensure a stable hydrostatic reference pressure. Because fluid viscosity and valve operating characteristics are temperature dependent, the test system was built into an incubator set at 37°C (Figure 1).
Solenoid valves were computer controlled and the system performed all steps of the pre-programmed test protocol automatically, including a two-point pressure recalibration at zero and 305 mm H2O before testing at each valve opening pressure setting. For each valve setting, the inlet pressure was gradually increased from zero to a maximum pressure and then back to zero according to a triangular shaped waveform with a cycle period of 60 min . The triangular wave was repeated 6 times at each setting for each valve for a total of 288 cycles. If air bubbles were detected during a cycle, the cycle was omitted (304 cycles with 16 omissions were necessary to achieve 288 cycles). Every shunt was tested at all eight opening pressure settings.
Opening conductance (1/Rout) was determined as the slope of a linear regression between 0.45 and 0.9 ml/min (Figure 2). The shunt valve opening pressure was considered to be the pressure value at the intersection of the regression line with the x-axis (i.e., zero flow). Results at each shunt setting are presented as the mean value of 6 cycles per shunt for all 6 shunts.
To test for differences between groups analysis of variance (ANOVA) with Bonferroni Post Hoc test were used. p < 0.05 was considered statistically significant.
This in vitro test of the Certas™ valve has demonstrated a reliable, consistent step-wise regulation of opening pressure with an acceptable outflow resistance for all shunt valve settings. The six tested shunts had similar characteristics and were well within the manufacturer’s specifications for opening pressure at settings 1–7, with no overlap between settings (Figure 3). For settings 1-7, the opening pressure ranged from 26 to 247 mm H2O. The increment between settings was 33–38 mm H2O (≈2.7 mm Hg), which is larger than the 10 mm H2O (0.7 mm Hg) increment for the Codman Hakim shunt  and more similar to increments for the Medtronic Strata shunt . For setting 8, “Virtual Off”, we determined the opening pressure was nearly 500 mm H2O, which is 100 mm H2O higher than the minimum of 400 mm H2O specified by the manufacturer. With the shunt implanted in patients, the cardiac related pulsations of intracranial pressure (ICP), in combination with the hysteresis characteristics of the valve (Figure 2) will probably result in the shunt operating within the boundaries of the hysteresis curve at each setting. Thus, the opening pressure of the shunt in a patient can be expected to be 10-25 mm H2O lower than the opening pressure determined by the test system.
In principle, the shunt’s main function is to create a CSF outflow pathway parallel to the patient’s CSF pathways, which are impaired and have increased CSF outflow resistance that plays a role in the pathophysiology of hydrocephalus. To anticipate an individual patient’s CSF dynamics after shunt surgery, it is essential to know the shunt operating characteristics and the patient’s preoperative CSF dynamics, which can be determined with an infusion test [3, 7]. Rout >18 mmHg/ml/min is considered indicative of a response to shunting in patients with idiopathic normal pressure hydrocephalus (iNPH) . The most important parameters for the shunt are the outflow resistance when the shunt is open, and the opening pressure of the valve at each setting.
The shunt outflow resistance describes the relationship between pressure and flow when the valve is open. The mean Rout is 7.0 mmHg/ml/min for the Certas™, and the variation between settings (6.7 to 7.3 mmHg/ml/min), while statistically significant, is small enough from a clinical perspective to be regarded as independent of the valve setting. In the test system, the mean Rout comprises the sum of Rout from the proximal catheter, the valve mechanism, and the distal catheter. From specifications provided in the shunt package insert, we can calculate that (1) the shunt valve Rout should be approximately 1.3 mmHg/ml/min, (2) the distal catheter Rout should be approximately 5.0 mmHg/ml/min, and if the proximal catheter resistance was approximately 0.7 mmHg/ml/min, the combined value is equal to the 7.0 mmHg/ml/min measured in this study. This is slightly higher than most shunts on the market [2–4].
The shunt outflow resistance of the Certas™ programmable valve (7.0 mmHg/ml/min) is lower than the physiological mean outflow resistance reported for patients with NPH (17.6 mmHg/ml/min)  and just below the median Rout (8.6 mmHg/ml/min) reported for healthy elderly . Therefore, in a patient with a shunt, the shunt will usually be the path of least resistance for CSF outflow, and it will dominate the CSF pathways, creating a low resistance CSF dynamic system whenever the valve is open. As a result, measurement of CSF outflow resistance can be used to determine if a shunt is functioning or obstructed. The Rout of a patient with an obstructed shunt is high, and usually similar to the patient’s pre-shunt Rout[10, 11]. In Europe, when patients are evaluated for suspected hydrocephalus, infusion testing is often used to characterize the CSF dynamic system to determine whether Rout is abnormal  and shunt malfunction is present [10, 13]. The expected Rout in a patient with a functioning Certas shunt should be in the range of 4.0 to 6.5 mmHg/ml/min (conductance 20 to 31 μl/s/kPa).
The opening pressure is the differential pressure across the valve mechanism needed for the valve mechanism to open. For example, with a ventriculo-peritoneal shunt configuration, for the valve to open when the patient is horizontal, the difference between the CSF pressure and the downstream pressure, which is the intra-abdominal pressure, must be greater than the valve opening pressure.
Recent reports support the use of a high valve setting on adjustable shunts as a noninvasive method to treat subacute or chronic subdural fluid collections or hematomas that have resulted from over drainage . The opening pressure of settings 6 and 7 of the Certas™ valve are both higher than the opening pressure of the highest setting of the Codman Hakim  and Strata shunts . We confirmed that the Certas™ valve setting 8, “Virtual Off”, has an opening pressure range of 451 to 556 mm H2O, which is significantly higher than the highest shunt setting of other adjustable valves, and can probably for most patients be regarded as functionally closed. Other potential uses for such high shunt settings include gradually raising the shunt setting in an attempt to make a patient shunt independent, or using the system as a “back up” after endoscopic third ventriculostomy (ETV), where the shunt would open at a very high CSF pressure that would occur if the ETV were to fail. The availability of higher opening pressures may also obviate the need for subsequent surgical implantation of an additional resistance device (anti-siphon device) in some patients. The proSA® shunt from Miethke has a comparable solution to the high pressure setting with an adjustable anti-gravitational device which can be adjusted to a counter pressure up to 400 mm H2O. However, in contrast to Certas™, the proSA® is only active in the upright position and in the supine position the opening pressure of that device is zero. Shunt system flow is then dependent on the opening pressure of the standard differential valve placed in series with the proSA®. Although not evaluated in this study, the Certas™ shunt system is available with the SiphonGuard™ anti-siphon device. In a previous study  we found that in the supine position neither the opening pressure nor the resistance was changed in the Codman Hakim valve system by adding the SiphonGuard™, nor were they affected by positioning the SiphonGuard™ either 10 cm above or 20 cm below the ventricular catheter tip. We expect that the same will hold for the Certas™ because the basic differential-pressure shunt design is the same.
An important question is whether the “Virtual Off” setting is likely to be functionally off in a patient. Portnoy et al. suggested that the perfusion pressure (PP) through the shunt is equal to: ICP + hydrostatic pressure – intra abdominal pressure – shunt opening pressure . The PP must be greater than zero for the valve to open and CSF to flow. In the supine position the hydrostatic pressure is zero. Abdominal pressure is normally in the range of 70 to 190 mm H2O, and is dependent on obesity . ICP in healthy elderly is 100 to 196 mm H2O  and in iNPH patients it is lower than 240 mm H2O . In overnight monitoring, ICP is shown to be slightly higher during sleep, but periods of ICP above 205 mm H2O are rare in communicating hydrocephalus . Plateau waves with large ICP increases could cause shunt flow, but they are not a typical feature in NPH patients . Thus, in the supine position, using the limits of normal values for each variable and an opening pressure of 400, we can calculate that PP = (240 + 0 – 70 - 400) = −230 and no CSF will flow through the Certas™ shunt.
In the sitting position ICP is approximately zero [18–20]. Abdominal pressure on average increases with 120 mm H2O in the 45° sitting position  and in NPH patients the abdominal pressure in the sitting position is between 150 mm H2O  and 240 mm H2O . The hydrostatic pressure will of course depend on the subject, but can be assumed around 500 to 600 mm H2O. The worst case scenario for upright PP = (0 + 600 – 150 - 400) = 50, which means that the Certas™ shunt valve could open. This shows that this limit is tight and that there is still risk for shunt flow. However, extrapolating the data from Miyake et al., who measured ICP and abdominal pressure with different shunt settings up 200 mm H2O, to a shunt opening pressure of 400 mm H2O, indicates that the flow would be zero in all but one of their patients. Considering that the Certas™ shunt in this study had a mean shunt opening pressure above the limit of 400 mm H2O for all shunts and that in individual subjects the body probably “self compensates” for a larger hydrostatic pressure gradient with a larger increase in abdominal pressure for a taller person, we believe that the “Virtual Off” setting in patients with iNPH should act essentially as an off setting for most patients. However, we emphasize that this needs to be verified in the clinical setting.
The “Virtual Off” setting has applicability for research protocols. This setting could be used to non-invasively turn on or off the shunt in a blinded protocol, which previously has required either surgical clipping of the shunt catheter at the time of implantation  or implantation of a “dummy” shunt with an internal occlusion . Reversal of the placebo condition in these studies required an additional surgical procedure, which is a significant risk from the perspective of research ethics, and may be a barrier to recruitment of research subjects. A blinded study design with randomization either to “Virtual Off” or usual functional opening pressure settings could determine the true clinical effect of shunt surgery, as well as determination of cerebral blood flow and metabolic responses induced by the changed CSF dynamics from the active shunting. The Certas™ is designed to prevent the shunt setting from changing in strong external magnetic fields, such as those associated with MRI , which would prevent inadvertent change of the shunt setting during the study protocol should the patient require an “off protocol” MRI for clinical purposes. Another important feature for the clinician is that, similar to the Medtronic Strata shunt the setting of the Certas™ shunt can be checked with an indicator tool, thereby avoiding unnecessary x-rays.
It should be noted that flow in the “Virtual Off” position has been considered here largely in normal and iNPH patients. In children and adults with typical “high” pressure hydrocephalus or with pseudotumour cerebri, flow may be present even at this setting. While this is likely a positive safety feature for patients with potentially high pressures and unlikely to impede its use for treatment of low pressure problems like subdurals, it should be realized that under these circumstances shunt removal or ligation differs from the “Virtual Off” setting.
In conclusion we confirmed that the opening pressures and outflow resistance of the Certas™ adjustable valve closely matched the manufacturer’s specifications; and that pressure measured at the “Virtual Off” setting exceeded 400 mm H2O for all shunts. The “Virtual Off” setting may be useful in clinical situations where a reversible and non-invasively “closed” shunt may be desired. The “Virtual Off” feature may reduce the need for surgery in the treatment of subdural hygromas and hematomas, failed third ventriculostomies and shunt weaning.
This study was supported by the Swedish Research Council, VINNOVA and the Swedish Foundation for Strategic Research through their joint initiative on Biomedical Engineering for Better Health.
- Hoya K, Tanaka Y, Uchida T, Takano I, Nagaishi M, Kowata K, Hyodo A: Treatment of traumatic acute subdural hematoma in adult hydrocephalus patients with cerebrospinal fluid shunt. Clin Neurol Neurosurg. 2012, 114: 211-216. 10.1016/j.clineuro.2011.10.002.PubMedView ArticleGoogle Scholar
- Lundkvist B, Eklund A, Koskinen LO, Malm J: An adjustable CSF shunt: advices for clinical use. Acta Neurol Scand. 2003, 108: 38-42.PubMedView ArticleGoogle Scholar
- Malm J, Lundkvist B, Eklund A, Koskinen LO, Kristensen B: CSF outflow resistance as predictor of shunt function. A long-term study. Acta Neurol Scand. 2004, 110: 154-160. 10.1111/j.1600-0404.2004.00302.x.PubMedView ArticleGoogle Scholar
- Arnell K, Koskinen LO, Malm J, Eklund A: Evaluation of Strata NSC and Codman Hakim adjustable cerebrospinal fluid shunts and their corresponding antisiphon devices. J Neurosurg Pediatr. 2009, 3: 166-172. 10.3171/2008.10.PEDS08118.PubMedView ArticleGoogle Scholar
- Hassan M, Higashi S, Yamashita J: Risks in using siphon-reducing devices in adult patients with normal-pressure hydrocephalus: bench test investigations with Delta valves. J Neurosurg. 1996, 84: 634-641. 10.3171/jns.1996.84.4.0634.PubMedView ArticleGoogle Scholar
- Malm J, Jacobsson J, Birgander R, Eklund A: Reference values for CSF outflow resistance and intracranial pressure in healthy elderly. Neurology. 2011, 76: 903-909. 10.1212/WNL.0b013e31820f2dd0.PubMedView ArticleGoogle Scholar
- Lundkvist B, Koskinen LO, Birgander R, Eklund A, Malm J: Cerebrospinal fluid dynamics and long-term survival of the Strata valve in idiopathic normal pressure hydrocephalus. Acta Neurol Scand. 2011, 124: 115-121. 10.1111/j.1600-0404.2010.01432.x.PubMedView ArticleGoogle Scholar
- Boon AJ, Tans JT, Delwel EJ, Egeler_Peerdeman SM, Hanlo PW, Wurzer HA, Avezaat CJ, de_Jong DA, Gooskens RH, Hermans J: Dutch normal-pressure hydrocephalus study: prediction of outcome after shunting by resistance to outflow of cerebrospinal fluid. J Neurosurg. 1997, 87: 687-693. 10.3171/jns.1997.87.5.0687.PubMedView ArticleGoogle Scholar
- Boon AJ, Tans JT, Delwel EJ, Egeler_Peerdeman SM, Hanlo PW, Wurzer HA, Avezaat CJ, de_Jong DA, Gooskens RH, Hermans J: Dutch Normal-Pressure Hydrocephalus Study: randomized comparison of low- and medium-pressure shunts. J Neurosurg. 1998, 88: 490-495. 10.3171/jns.1998.88.3.0490.PubMedView ArticleGoogle Scholar
- Eklund A, Lundkvist B, Koskinen LO, Malm J: Infusion technique can be used to distinguish between dysfunction of a hydrocephalus shunt system and a progressive dementia. Med Biol Eng Comput. 2004, 42: 644-649. 10.1007/BF02347546.PubMedView ArticleGoogle Scholar
- Petrella G, Czosnyka M, Smielewski P, Allin D, Guazzo EP, Pickard JD, Czosnyka ZH: In vivo assessment of hydrocephalus shunt. Acta Neurol Scand. 2009, 120: 317-323. 10.1111/j.1600-0404.2009.01176.x.PubMedView ArticleGoogle Scholar
- Malm J, Sundstrom N, Cesarini KG, Edsbagge M, Kristensen B, Leijon G, Eklund A: Implementation of a new CSF dynamic device: a multicenter feasibility study in 562 patients. Acta Neurol Scand. 2012, 125: 199-205. 10.1111/j.1600-0404.2011.01533.x.PubMedView ArticleGoogle Scholar
- Czosnyka ZH, Czosnyka M, Pickard JD: Shunt testing in-vivo: a method based on the data from the UK shunt evaluation laboratory. Acta Neurochir Suppl. 2002, 81: 27-30.PubMedGoogle Scholar
- Zemack G, Romner B: Adjustable valves in normal-pressure hydrocephalus: a retrospective study of 218 patients. Neurosurgery. 2002, 51: 1392-1400.PubMedGoogle Scholar
- Portnoy HD, Schulte RR, Fox JL, Croissant PD, Tripp L: Anti-siphon and reversible occlusion valves for shunting in hydrocephalus and preventing post-shunt subdural hematomas. J Neurosurg. 1973, 38: 729-738. 10.3171/jns.1973.38.6.0729.PubMedView ArticleGoogle Scholar
- De Keulenaer BL, De Waele JJ, Powell B, Malbrain ML: What is normal intra-abdominal pressure and how is it affected by positioning, body mass and positive end-expiratory pressure?. Intensive Care Med. 2009, 35: 969-976. 10.1007/s00134-009-1445-0.PubMedView ArticleGoogle Scholar
- Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM: Diagnosing Idiopathic Normal-pressure Hydrocephalus. Neurosurgery. 2005, 57: 4-16.Google Scholar
- Stephensen H, Tisell M, Wikkelso C: Intracranial pressure during wakefulness and sleep in 55 adult patients with chronic hydrocephalus. Neurosurgery. 2006, 59: 326-332. 10.1227/01.NEU.0000223513.89586.9A.PubMedView ArticleGoogle Scholar
- Miyake H, Ohta T, Kajimoto Y, Nagao K: New concept for the pressure setting of a programmable pressure valve and measurement of in vivo shunt flow performed using a microflowmeter. Technical note. J Neurosurg. 2000, 92: 181-187. 10.3171/jns.2000.92.1.0181.PubMedView ArticleGoogle Scholar
- Bergsneider M, Yang I, Hu X, McArthur DL, Cook SW, Boscardin WJ: Relationship between Valve Opening Pressure, Body Position, and Intracranial Pressure in Normal Pressure Hydrocephalus: Paradigm for Selection of Programmable Valve Pressure Setting. Neurosurgery. 2004, 55: 851-859. 10.1227/01.NEU.0000137631.42164.B8.PubMedView ArticleGoogle Scholar
- Tisell M, Tullberg M, Hellstrom P, Edsbagge M, Hogfeldt M, Wikkelso C: Shunt surgery in patients with hydrocephalus and white matter changes. J Neurosurg. , 114: 1432-1438.Google Scholar
- Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D: Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Neurology. 2008, 71: 202-209. 10.1212/01.wnl.0000316197.04157.6f.PubMedView ArticleGoogle Scholar
- Shellock FG, Bedwinek A, Oliver-Allen M, Wilson SF: Assessment of MRI issues for a 3-T “immune” programmable CSF shunt valve. AJR Am J Roentgenol. 2012, 197: 202-207.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.